Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Regeneron Pharmaceuticals 777 OLD SAW MILL RIVER ROAD TARRYTOWN NY 10591 USA

www.regeneron.com Employees: 15,106 P: 914-847-7000

Sector:

Medical

Description:

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.

Key Statistics

Overview:

Market Capitalization, $K 64,405,432
Enterprise Value, $K 63,901,632
Shares Outstanding, K 107,965
Annual Sales, $ 14,202 M
Annual Net Income, $ 4,413 M
Last Quarter Sales, $ 3,029 M
Last Quarter Net Income, $ 808,700 K
EBIT, $ 3,831 M
EBITDA, $ 4,314 M
60-Month Beta 0.43
% of Insider Shareholders 7.02%
% of Institutional Shareholders 83.31%
Float, K 100,386
% Float 92.98%
Short Volume Ratio 0.50

Growth:

1-Year Return -38.49%
3-Year Return -13.89%
5-Year Return -2.65%
5-Year Revenue Growth 80.61%
5-Year Earnings Growth 79.88%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 8.22 on 04/29/25
Next Earnings Date N/A
Earnings Per Share ttm 38.16
EPS Growth vs. Prev Qtr -35.05%
EPS Growth vs. Prev Year -19.32%
Annual Dividend Rate, $ 0.88
Annual Dividend Yield 0.15%
Most Recent Dividend 0.880 on 05/20/25
Next Ex-Dividends Date 05/20/25
Dividend Payable Date 06/06/25
Dividend Payout Ratio 2.14%

REGN Ratios

Ratio
Price/Earnings ttm 15.57
Price/Earnings forward 20.27
Price/Earnings to Growth 2.31
Return-on-Equity % 15.27%
Return-on-Assets % 11.93%
Profit Margin % 31.07%
Debt/Equity 0.07
Price/Sales 4.52
Price/Cash Flow 13.01
Price/Book 2.18
Book Value/Share 272.18
Interest Coverage 87.59

REGN Dividends

Date Value
05/20/25 $0.8800
02/20/25 $0.8800
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar